Fedley Healthcare: India's Trusted Permethrin 5% w/w + citramide 1% Lotion

DCGI Approved WHO-GMP
Lotion/Facewash/Solutions

RIVTHERIN

Product Composition

Permethrin 5% w/w + citramide 1% Lotion

Packing
60ML
Release Type
Pet Bottle
DCGI Approved
WHO-GMP Certified
Pet Bottle
Pan India Delivery
Product Price
MRP (Inclusive of all taxes)
₹82.5
Get Franchise QuoteWhatsApp Us
ISO 9001:2015
1000+ Products
29+ States
Share:

Uses of RIVTHERIN

Permethrin 5% w/w + citramide 1% Lotion is prescribed for various conditions related to inflammation, pain, and joint disorders.

Quality-Driven Manufacturing Behind RIVTHERIN

1000+
DCGI Approved Products
12+
Years of Experience
2000+
Franchise Partners
29+
States Covered

PCD Pharma Franchise for Permethrin 5% w/w + citramide 1% Lotion — Available Across India

Fedley Healthcare provides exclusive monopoly-based PCD franchise rights for RIVTHERIN in all major states and union territories across India.

PunjabHaryanaRajasthanUttar PradeshMadhya PradeshGujaratMaharashtraKarnatakaTamil NaduKeralaAndhra PradeshTelanganaWest BengalBiharJharkhandOdishaChhattisgarhAssamMeghalayaTripuraManipurNagalandMizoramArunachal PradeshSikkimUttarakhandHimachal PradeshGoaJammu & KashmirDelhi NCRChandigarhPuducherry

Exclusive monopoly rights available — contact us to check availability in your state & district.

Why Fedley Healthcare vs Other Manufacturers?

See how we compare with typical pharma manufacturers in India.

Factor
Fedley Healthcare
Others
WHO-GMP Certification
Certified
Often Not
DCGI Approved Products
1000+
Limited
Monopoly Rights
Exclusive Territory
Shared
Marketing Support
Visual Aids, LBLs, Gifts
Minimal / Paid
Product Quality
SR Technology
Standard
Delivery
Pan India, On-Time
Delayed
MOQ (Min Order)
Flexible & Low
High Minimum
Profit Margins
Attractive (High ROI)
Thin Margins
Ethical Promotion
100% Ethical
Questionable
Franchise Support
Dedicated Manager
No Post-Sale Support
WHO-GMP Certification
Fedley
Certified
Others
Often Not
DCGI Approved Products
Fedley
1000+
Others
Limited
Monopoly Rights
Fedley
Exclusive Territory
Others
Shared
Marketing Support
Fedley
Visual Aids, LBLs, Gifts
Others
Minimal / Paid
Product Quality
Fedley
SR Technology
Others
Standard
Delivery
Fedley
Pan India, On-Time
Others
Delayed
MOQ (Min Order)
Fedley
Flexible & Low
Others
High Minimum
Profit Margins
Fedley
Attractive (High ROI)
Others
Thin Margins
Ethical Promotion
Fedley
100% Ethical
Others
Questionable
Franchise Support
Fedley
Dedicated Manager
Others
No Post-Sale Support

Start Your Pharma Business with RIVTHERIN — Get Exclusive Franchise Rights in Your State Today

Join 2000+ successful franchise partners across India. Low investment, high returns, complete marketing support.

Get Franchise Quote Now

Get Franchise Quote for RIVTHERIN

Interested in Permethrin 5% w/w + citramide 1% Lotion for your pharma franchise business? Fill the form and our team will get back to you with pricing, MOQ, and exclusive territory details.

  • Exclusive Monopoly Rights in Your Territory
  • Attractive Profit Margins & Low Investment
  • Timely Product Delivery Across India
  • Free Promotional Support (Visual Aids, LBLs, Gifts)

Send Enquiry

Fill in your details and we'll contact you shortly.

Product: RIVTHERIN | Permethrin 5% w/w + citramide 1% Lotion

Or call us: +91-9855986633 | +91-9317692852

Customer Reviews

4.8based on 124 ratings

Very satisfied with RIVTHERIN. The quality of Permethrin 5% w/w + citramide 1% Lotion is pharmaceutical-grade and meets all WHO-GMP standards. Reliable product from Fedley Healthcare.

SR

Suresh Reddy

Verified Purchase

8 Jul 2025

RIVTHERIN from Fedley Healthcare is a dependable product. Permethrin 5% w/w + citramide 1% Lotion — the composition is clinically relevant and competitively priced for franchise partners.

DR

Dr. Rekha Mishra

Verified Purchase

10 Dec 2025

RIVTHERIN has been a valuable addition to my product portfolio. Permethrin 5% w/w + citramide 1% Lotion is an effective composition and Fedley ensures premium manufacturing standards.

JK

Joginder Koul

Verified Purchase

18 Feb 2026